Skip to main content
HR 6710 117th Congress House Health Congressional oversight Drug safety, medical device, and laboratory regulation Emergency medical services and trauma care Infectious and parasitic diseases Manufacturing Trade restrictions

To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic…

Show full title

To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices, and for other purposes.

Introduced: February 11, 2022 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 14, 2022
Referred to the Subcommittee on Health.
Feb 11, 2022
Referred to the House Committee on Energy and Commerce.
Feb 11, 2022
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

This bill requires the Food and Drug Administration (FDA) to report to Congress on barriers to the domestic manufacturing of imported active pharmaceutical ingredients, finished drug products, and devices that are critical to public health.

The report must recommend strategies to overcome such barriers. The FDA may, to the extent appropriate, implement the strategies.

What's happening now February 14, 2022

Referred to the Subcommittee on Health.

 Related & companion bills 1
  • HR 4792 Related bill Countering Communist China Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 20
All 20 Republican 13
Mooney, Alexander
· Mar 24, 2022
 R
Jackson, Ronny
Texas · Mar 7, 2022
Hartzler, Vicky
· Feb 22, 2022
 R
Babin, Brian
Texas · Feb 18, 2022
 R
Mann, Tracey
Kansas · Feb 15, 2022
 R
Banks, Jim
Indiana · Feb 11, 2022
 R
Cammack, Kat
Florida · Feb 11, 2022
Cawthorn, Madison
· Feb 11, 2022
 R
Donalds, Byron
Florida · Feb 11, 2022
Gohmert, Louie
· Feb 11, 2022
 R
Hern, Kevin
Oklahoma · Feb 11, 2022
 R
Higgins, Clay
Louisiana · Feb 11, 2022
 R
Hudson, Richard
North Carolina · Feb 11, 2022
Keller, Fred
· Feb 11, 2022
LaTurner, Jake
· Feb 11, 2022
McKinley, David
· Feb 11, 2022
 R
Miller, Mary E.
Illinois · Feb 11, 2022
 R
Miller-Meeks, Mariannette
Iowa · Feb 11, 2022
 R
Norman, Ralph
South Carolina · Feb 11, 2022
 R
Scott, Austin
Georgia · Feb 11, 2022
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 6710: To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices, and for other purposes.. 117th Congress. Open America. https://openamerica.io/bill/117-HR-6710/
MLA
"H.R. 6710: To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices, and for other purposes.." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-6710/.
Bluebook (legal)
H.R. 6710, 117th Cong. (2026), https://openamerica.io/bill/117-HR-6710/.
Markdown link
[H.R. 6710: To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices, and for other purposes.](https://openamerica.io/bill/117-HR-6710/)
Report a problem